Evidence map›Paper›PMID 31605190›Full record

ReviewEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2019

Demystifying autoimmune inner ear disease.

Soumyajit Das, Satvinder Singh Bakshi, Ramesh Seepana

Abstract readReview
PubMed Publisher
In one paragraph

Review in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Type 1 diabetes mellitus increases the risk of sudden sensorineural hearing loss: A two-sample Mendelian randomization study.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
    Article
  8. Review
  9. Article
  10. Autoimmune Hearing Loss: A Diagnostic Challenge.Journal of clinical medicine · 2022
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. [Clinical characteristics and prognosis of sudden sensorineural hearing loss with rheumatoid arthritis].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2021
    Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Soumyajit DasDepartment of ENT, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, 522503, India. drsoumya_entamch@rediffmail.com.ORCID http://orcid.org/0000-0003-2293-5547
Satvinder Singh BakshiDepartment of ENT, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, 522503, India.
Ramesh SeepanaDepartment of ENT, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, 522503, India.
All India Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAutoimmune inner disease (AIED) is an uncommon cause of sensorineural hearing loss and poses a diagnostic challenge. The present study aims to review the existing knowledge on the clinicopathological aspects, the diagnostic challenges, and therapeutic interventions in AIED. DISCUSSION: The incidence of AIED is less than five cases per 100,000 population. There are no definite seromarkers which make diagnosis of AIED difficult. Even though various markers have been studied, their sensitivity and specificity have not been replicated in the clinical scenario. The treatment of the condition is also an enigma. Corticosteroids are the drug of choice and require long-term use to prevent relapse. Various other therapeutic agents have been studied in a small cohort of patients, but the efficacy of these drugs needs to be validated in a large multicentric trial.

conclusionTimely intervention can restore hearing loss in AIED patients, but the clinician has to find a delicate balance between the hearing outcome and the potential side effects resulting from long-term use of the drugs. Treatment of steroid resistant AIED is a challenge and there are no universal guidelines for the same. AIED being an uncommon diagnosis, multicentric trials and collaboration are required to formulate diagnostic criteria and therapeutic guidelines.

Indexed as

Adrenal Cortex HormonesAdultAutoimmune DiseasesEar, InnerFemaleGlucocorticoidsHearing Loss, SensorineuralHumansImmunosuppression TherapyImmunosuppressive AgentsLabyrinth DiseasesMagnetic Resonance ImagingMalePositron-Emission TomographyTreatment OutcomeAdrenal Cortex HormonesGlucocorticoidsImmunosuppressive AgentsAutoimmunityCirculating antibodiesDiagnosisHearing lossInner earInner ear antigensMagnetic resonance imagingPositron emission tomographySensorineural

Identifiers

PMID31605190
OpenAlexW2979337522

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.